Today
Nature’s Care sale docs in front of potential buyers; NBIOs due Sept 6
Although the company returned a $23.7 million operating profit in 2023, it has struggled under a heavy debt load and missed a $148 million debt payment last month.
- 1 hr ago
- Sarah Thompson, Kanika Sood and Emma Rapaport
Competition regulator delays $8.8b Chemist Warehouse deal approval
The ACCC is undertaking more analysis of the transaction, which would merge the pharmacy giant into Sigma Healthcare. A decision won’t be made until October.
- 1 hr ago
- Michael Smith
This Month
Houlihan Lokey tapped for Nature’s Care sale
Street Talk can reveal receivers BDO Australia called in Houlihan Lokey to kick off a sale process.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Exclusive
- Weight loss
Ozempic maker wants taxpayer subsidy for new Wegovy drug
Danish pharmaceutical giant Novo Nordisk pulled in more than $600 million from Australia last year but reported just $17 million in profit here.
- Nick Bonyhady
- Exclusive
- Weight loss
Next blockbuster weight-loss drug to launch in Australia this month
Novo Nordisk’s Wegovy is about to go on sale here, avoiding the prospect of a supply disaster when compounded Ozempic is banned.
- Updated
- Nick Bonyhady
July
Nasal viagra biotech launches capital raising, Alpine on ticket
Street Talk understands sole lead manager Alpine Capital was seeking bids at 73¢ per share on Monday morning.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Why testosterone is a wonder drug for men and women over 50
More than just a male sex hormone, it can be the foundation for a healthy lifestyle – and the Olympics is about to put its powers under the spotlight again.
- Hattie Garlick
Want to live to 100? Maybe try this new supplement
Can the latest longevity pill help restore your youthful vigour and avoid age-related disease? Be warned: there may be risks.
- David Cox
Study finds a treatment more effective than Ozempic for slimming down
The analysis found a rival drug made by Eli Lilly leads to faster and better weight loss, causing shares in to Wegovy maker Novo Nordisk’s to also drop.
- Reuters
Pharmacies face an ‘Uber’ moment – whether they like it or not
Stephen King, who led a Health Department review into the sector, says antiquated ownership restrictions should be abolished before they do more damage.
- Carrie LaFrenz
Ozempic could be linked to sudden blindness, says new report
Patients who took the drugs for weight loss were seven times more likely to be diagnosed with a stroke-like eye condition, according to Harvard research.
- Robert Langreth
June
Vapes would be sold like cigarettes under Coalition policy
Vapes would be subject to an excise tax that could raise billions of dollars annually, under a proposal unveiled by shadow health spokeswoman Anne Ruston.
- Ronald Mizen
The Ozempic effect: How weight loss wonder drug gobbled up an economy
Pharmaceutical giant Novo Nordisk has grown so large in its native Denmark that it’s hard to find staff. Meanwhile, its philanthropic foundation is running out of local causes to support.
- Sanne Wass and Naomi Kresge
How to keep off the kilos after stopping weight-loss jabs
Until now, those prescribed the radical treatments have been warned that they may have to stay on the drugs for life – or revert to their former size.
- Laura Donnelly
- Exclusive
- Industrial
More cold sheds needed to supply veg and meds
Australia will have to ramp up its construction of cold storage sheds to service the food supply needs of our booming population, says CBRE.
- Larry Schlesinger
Telix pulls $300m Nasdaq IPO as investors demand deep discount
The cancer treatment hopeful had announced plans to list in New York only last week as it searched for more capital. On Friday, it withdrew from the initial public offering.
- Kylar Loussikian
- Updated
- Mergers & acquisitions
Chemist Warehouse may have to sell stores to save merger
Chemist Warehouse may have to sell off part of its store network to convince the competition regulator that plans to merge with Sigma would not lessen competition and lead to higher prices.
- Updated
- Carrie LaFrenz and Tom Richardson
- Opinion
- Chanticleer
Chemist Warehouse deal can still get past ACCC health check
The issue of the competitiveness of Sigma’s pharmacies may require a more direct solution, such as disposing of a few Chemist Warehouse outlets.
- Updated
- James Thomson
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
Immutep raises $100m and signs with Merck on ‘blockbuster’ drug
Shares in the oncology therapy hopeful have risen some 45 per cent in the last 12 months as the company nears the commercialisation of its drug, Efti.
- Kylar Loussikian
